Literature DB >> 6861855

Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration.

H Bergrem, P Grøttum, H E Rugstad.   

Abstract

The pharmacokinetics of prednisolone after oral and intravenous administration of 10 and 20 mg have been studied. Serum protein binding of prednisolone was also measured after the i.v. injections. The bioavailability after oral administration was 84.5% after 10 mg and 77.6% after 20 mg (p greater than 0.05). Dose dependent pharmacokinetics were found, the VDss and Clt being significantly larger (p less than 0.01) after 20 mg i.v. than after 10 mg i.v. The protein binding of prednisolone in all subjects was non-linear, and is the most likely cause of the dose dependent pharmacokinetics, as there was no dose dependent variation in elimination half-time.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861855     DOI: 10.1007/bf00610064

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Dose-dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J C Loo; I J McGilveray; N Jordan; J Moffat; R Brien
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

2.  Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone.

Authors:  R G Henderson; T Wheatley; J English; J Chakraborty; V Marks
Journal:  Br Med J       Date:  1979-06-09

Review 3.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  M E Pickup
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

4.  Dose-dependent prednisolone kinetics.

Authors:  A Tanner; F Bochner; J Caffin; J Halliday; L Powell
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

5.  Plasma protein binding of prednisolone in normal volunteers and arthritic patients.

Authors:  I T Ağabeyoğlu; R F Bergstrom; W R Gillespie; J G Wagner; D R Kay
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

6.  Immunosuppressive treatment policies. A) Glucocorticoids: absorption of prednisolone. I. The effect of fasting, food, and food combined with antacids.

Authors:  H Bergrem; O Djøseland; J Jervell; H E Rugstad
Journal:  Scand J Urol Nephrol Suppl       Date:  1981

7.  Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients.

Authors:  F J Frey; W J Amend; F Lozada; B M Frey; N H Holford; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

9.  Effectiveness of prednisolone during phenytoin therapy.

Authors:  L B Petereit; A W Meikle
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

10.  Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients.

Authors:  J G Gambertoglio; F Vincenti; N J Feduska; J Birnbaum; O Salvatierra; W J Amend
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  15 in total

1.  Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man.

Authors:  J A Wald; R M Law; E A Ludwig; R R Sloan; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

2.  Correction for Volume Shift during Equilibrium Dialysis by Measurement of Protein Concentration.

Authors:  K M Giacomini; F M Wong; T N Tozer
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

3.  Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.

Authors:  Marija Tubic-Grozdanis; Michael B Bolger; Peter Langguth
Journal:  AAPS J       Date:  2008-04-02       Impact factor: 4.009

Review 4.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  B M Frey; F J Frey
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

6.  The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.

Authors:  F J Frey; M K Rüegsegger; B M Frey
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

Review 7.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.

Authors:  Luc J J Derijks; Dennis R Wong; Daniel W Hommes; Adriaan A van Bodegraven
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

8.  Intra-individual consistency of prednisolone kinetics during long-term prednisone treatment.

Authors:  E Langhoff; H Flachs; J Ladefoged; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma.

Authors:  B Grandordy; N Belmatoug; A Morelle; D De Lauture; J Marsac
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

10.  Ketoprofen and prednisolone do not modulate neutrophil CR1, CR3 and Fc gamma RIII expression in healthy volunteers.

Authors:  F Laroche; A Kahan; A Kahan; M Letrait; C Cohen; P Jamin; G Strauch
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.